Do you want to read an article? Please log in or register.
Ixekizumab provides superior efficacy compared to ustekinumab over 52-weeks of treatment: results from IXORA-S, a phase 3 study
Psoriasis
Related content
COMMENTED
Psoriatic Arthritis
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Rheumatology (Oxford).
van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L
doi: 10.1093/rheumatology/kez420.
Psoriasis
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)
J Eur Acad Dermatol Venereol.
Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M
doi: 10.1111/jdv.16558.
Psoriasis
Efficacy and Safety of Ixekizumab in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Paediatric Patients with Moderate-to-Severe Plaque Psoriasis (IXORA-PEDS)
Br J Dermatol.
Paller AS, Seyger MMB, Magariños GA, Bagel J, Pinter A, Cather J, Keller S, Capriles CR, Lima RG, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K, IXORA-PEDS study group.
doi: 10.1111/bjd.19147.
COMMENTED
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results
Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Baek I, Ghil J
doi: 10.1002/art.40444.
Psoriasis
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, Phase 3 NAVIGATE trial
Br J Dermatol.
Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L
doi: 10.1111/bjd.15750.
Psoriasis
Clinical Similarity of the Biosimilar ABP 501 Compared With Adalimumab After Single Transition: Long-Term Results From a Randomised, Double-Blind, 52-Week, Phase 3 Study in Moderate-to-Severe Plaque Psoriasis Patients
Br J Dermatol.
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B
doi: 10.1111/bjd.15857.
Spinal Disorders
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Ann Rheum Dis.
Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS, COAST-V and COAST-W Study Groups.
doi: 10.1136/annrheumdis-2019-216118.
Psoriasis
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial
J Am Acad Dermatol.
Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA
doi: 10.1016/j.jaad.
Psoriasis
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Lancet
Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M
doi: 10.1016/S0140-6736(21)00125-2